Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Taranabant CB1 Receptor Inverse Agonist for Management of Obe

Drug (Brand/Generic)

Taranabant

Company/Licensee

Merck & Co

Therapy Class

Selective cannabinoid-1 (CB1) receptor inverse agonist

Product Description

Binds to the CB1 endocannabinoid receptor

Current Indication

Treatment of obesity in combination with dietary control

Market Sector

Nutrition

Development Status

Cancelled
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top